What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Paul S. Gaynon spends much of his time researching Internal medicine, Acute lymphocytic leukemia, Surgery, Oncology and Cancer.
His study in Gastroenterology extends to Internal medicine with its themes.
The Acute lymphocytic leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Clinical trial, Hematology, Randomized controlled trial and El Niño.
His Surgery research includes themes of Infant Acute Lymphoblastic Leukemia, Leukemia, Bone marrow and Hazard ratio.
His work carried out in the field of Oncology brings together such families of science as Trisomy, Childhood leukemia and Aneuploidy.
His Cancer research is multidisciplinary, incorporating elements of Risk factor and Lymphoblastic Leukemia.
His most cited work include:
- Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. (717 citations)
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group (670 citations)
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (515 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Acute lymphocytic leukemia, Cancer and Chemotherapy.
His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine.
His Oncology research incorporates elements of Clinical trial, Childhood leukemia, Asparaginase, Lymphoblastic Leukemia and Minimal residual disease.
His Acute lymphocytic leukemia research includes elements of Immunophenotyping, El Niño, Randomized controlled trial and Bone marrow.
As part of one scientific family, Paul S. Gaynon deals mainly with the area of Cancer, narrowing it down to issues related to the Pediatrics, and often Retrospective cohort study and Precursor Cell Lymphoblastic Leukemia Lymphoma.
The concepts of his Chemotherapy study are interwoven with issues in Cohort and Bortezomib.
He most often published in these fields:
- Internal medicine (73.80%)
- Oncology (44.65%)
- Acute lymphocytic leukemia (38.75%)
What were the highlights of his more recent work (between 2013-2020)?
- Internal medicine (73.80%)
- Oncology (44.65%)
- Lymphoblastic Leukemia (20.66%)
In recent papers he was focusing on the following fields of study:
Paul S. Gaynon mostly deals with Internal medicine, Oncology, Lymphoblastic Leukemia, Leukemia and Childhood leukemia.
Paul S. Gaynon has included themes like Gastroenterology and Pediatrics in his Internal medicine study.
His studies in Oncology integrate themes in fields like Young adult, Childhood Acute Lymphoblastic Leukemia, Asparaginase and Toxicity.
His study in the fields of Acute leukemia under the domain of Leukemia overlaps with other disciplines such as Azacitidine.
His Childhood leukemia study combines topics from a wide range of disciplines, such as Etoposide, Hematopoietic stem cell transplantation, Clinical trial and Lymphoma.
His studies deal with areas such as Surgery, Bioinformatics, T cell, High Resolution Melt and Acute lymphocytic leukemia as well as Minimal residual disease.
Between 2013 and 2020, his most popular works were:
- Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. (268 citations)
- Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group (81 citations)
- Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. (55 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Childhood leukemia, Leukemia and Chemotherapy.
His works in Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia, Toxicity, Young adult and Induction chemotherapy are all subjects of inquiry into Internal medicine.
His research in Oncology intersects with topics in Odds ratio, Minimal residual disease, Very high risk, Philadelphia chromosome and Cohort.
His Minimal residual disease study combines topics in areas such as Surgery, Cyclophosphamide, Nelarabine, Acute lymphocytic leukemia and Performance status.
His work deals with themes such as Etoposide, Bone marrow and Lymphoma, which intersect with Childhood leukemia.
His study explores the link between Leukemia and topics such as Myeloid that cross with problems in Multicenter study, Clinical trial and KMT2A.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
